PF-Atlas › Clinical Trials › NCT00125385
Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis
GC1008 · Phase 1
Registry ID
NCT00125385
Phase
Phase 1
Status
Completed
Drug / intervention
GC1008
Sponsor
Genzyme, a Sanofi Company
Start
2005-07
Enrollment
25
Locations
8
About this trial
This study is designed to investigate whether GC1008, an antibody that neutralizes TGFb, is safe in treating patients with idiopathic pulmonary fibrosis. The highest dose without excessive side effects will be identified. Tests will determine how long GC1008 is in the body and how it is excreted.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00125385 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.